RHP - Roman House Productions

The Boehringer Ingelheim-Pfizer deal includes products in the United States, Australia, Canada and South Africa, as well as two manufacturing and research facilities located in Fort Dodge, Iowa. Products being acquired in Europe are still subject to approval by European anti-trust authorities.

As part of the deal, Boehringer Ingelheim will acquire the Duramune line of vaccines for dogs, the Fel-O-Vax line of vaccines for cats and the Rabvac line of rabies vaccines manufactured and sold in the United States, Canada and Australia. The company will also acquire a portfolio of pet and equine pharmaceutical products currently sold in the United States.

In addition, the company will acquire cattle vaccines in the United States and Canada, including the Triangle, Pyramid and Presponse vaccine lines. Pharmaceutical products being acquired include Cydectin (moxidectin) for cattle and sheep as well as Polyflex (ampicillin sodium). The dairy portfolio includes the brands Today and Tomorrow.

"The products included in this acquisition complement our already strong product lines and help to broaden our innovation base across more species and boost our global pipeline," said Prof. Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim. "We look forward to applying our innovative culture to the products included in this acquisition as well as to the research and discovery of new products that will continue to bring value to our customers and our business."